Thoratec buys maker of transapical systems for $35M

Candace Stuart | | Cardiovascular Business | Heart Failure

Thoratec, which makes implantable devices for patients with advanced heart failure, paid $35 million to acquire an Irish company that specializes in transapical surgical access systems.

Pleasanton, Calif.-based Thoratec bought Apica Cardiovascular Limited for $35 million in cash with the potential payout of another $40 million contingent on clinical and sales milestones. The transaction allows Thoratec to take over development and commercialization of Apica’s Ventricular Assist Device (VAD) Surgical Implant System and the Apica Access Stabilization and Closure device. The technologies facilitate in transcatheter aortic valve replacement and transcatheter mitral valve replacement procedures using a transapical approach.

Thoratec makes the HeartMate II and HeartMate III Left Ventricular Assist Systems and Thoratec VAD. In a release, Thoratec President and CEO Gary F. Burbach said the deal will strengthen Thoratec’s market position by providing products customized for VAD procedures.

Thoratec is targeting the access stabilization and closure system as a support for less invasive and off-pump implantation of HeartMate devices. The system received CE mark in 2013.

Candace Stuart, Contributor

Related Content

FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
‘Incredibly rewarding’: FDA expands total artificial heart study after early success
Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker
Cardiologists work to standardize the diagnosis and management of acute myocarditis
FDA approves J&J MedTech’s Impella heart pumps to treat pediatric patients
Genetic predisposition to depression increases CVD risk in women, but not men

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.